Tag Archives: epidiolex

UK developer of medical cannabis products raises $345m through share sale

Source: The Pharmaceutical Journal9 OCT 2018By Debbie Andalo UK-based GW Pharmaceuticals has sold almost two million shares in a recent offering on the US stock exchange. Source: GW Pharmaceuticals GW Pharmaceuticals, which has previously marketed cannabis-derived medicines Sativex and Epidiolex, has raised over $345m from share sales in the United States The UK biopharmaceutical company GW Pharmaceuticals, a global developer of

Read more

DEA Green Lights Epidiolex as First Cannabis Derived Pharmaceutical

SOURCE: https://www.newcannabisventures.com/dea-green-lights-epidiolex-as-first-cannabis- September 27, 2018 at 9:22 am Breaking News by Alan Brochstein, CFA The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V status according to the Office of the Federal Register. The developer of the pharmaceutical, GW Pharma (NASDAQ:

Read more